ATP1B3, also known as the beta-3 subunit of the Na+/K+-ATPase pump, plays a fundamental role in maintaining the electrochemical gradients of sodium and potassium ions across the plasma membrane. This gradient is essential for various cellular processes, including cell volume regulation, and the transport of nutrients and neurotransmitters. The expression of ATP1B3 is a tightly regulated process within cells, and understanding the mechanisms behind its upregulation can provide insights into cellular adaptations to various physiological stimuli. Certain compounds are known to induce the expression of genes like ATP1B3 by interacting with specific cellular pathways or regulatory elements within the gene's promoter region.
Compounds such as retinoic acid and forskolin are examples of molecules that can potentially induce the expression of ATP1B3. Retinoic acid, a metabolite of vitamin A, is known for its influential role in cell growth and differentiation. It can potentially upregulate ATP1B3 by binding to retinoic acid receptors, which then interact with DNA at specific response elements to activate transcription. Forskolin, a plant-derived compound, is known for increasing intracellular cAMP, which in turn activates protein kinase A (PKA). Activation of PKA can lead to enhanced transcription of targeted genes, including ATP1B3. This transcriptional activation occurs through the phosphorylation of transcription factors and alteration of chromatin structure, thereby increasing gene expression. Other compounds such as vitamin D3, estrogen, and certain inhibitors like sunitinib or PD 173074, also demonstrate the capability to potentially induce ATP1B3 expression through their respective signaling pathways. These pathways converge on the transcriptional machinery of the cell, ultimately leading to increased production of the ATP1B3 protein, which is pivotal for the cell's ionic balance and overall function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid may upregulate ATP1B3 through the activation of nuclear retinoic acid receptors, leading to alterations in DNA transcription processes and initiating the synthesis of ATP1B3 mRNA. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin may raise intracellular cAMP levels, which in turn could activate protein kinase A (PKA) and lead to an increase in the transcriptional activity of genes including ATP1B3. | ||||||
L-3,3′,5-Triiodothyronine, free acid | 6893-02-3 | sc-204035 sc-204035A sc-204035B | 10 mg 100 mg 250 mg | $40.00 $75.00 $150.00 | ||
T3 could stimulate the transcription of ATP1B3 by binding to thyroid hormone response elements in the gene's promoter region, thereby initiating the production of the ATP1B3 protein. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $76.00 $82.00 $367.00 | 36 | |
Dexamethasone may stimulate the expression of ATP1B3 by interacting with glucocorticoid response elements in the gene's promoter, leading to enhanced transcription and subsequent translation. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium may upregulate ATP1B3 expression via the inhibition of glycogen synthase kinase-3, which could lead to increased transcriptional activity of genes involved in ionic transport. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $62.00 $178.00 | 8 | |
β-Estradiol has the potential to stimulate ATP1B3 gene expression by estrogen receptor-mediated interaction with estrogen response elements in the gene's promoter region. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib, a VEGF receptor inhibitor, could upregulate ATP1B3 by attenuating VEGF-mediated signaling pathways, possibly leading to a compensatory increase in ATP1B3 expression. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074, a selective FGF receptor inhibitor, may lead to an increase in ATP1B3 expression as a homeostatic response to disrupted FGF-mediated growth and differentiation pathways. | ||||||
Hydrocortisone | 50-23-7 | sc-300810 | 5 g | $100.00 | 6 | |
Hydrocortisone could stimulate ATP1B3 expression by binding to the glucocorticoid receptor, which may interact with glucocorticoid response elements upstream of the ATP1B3 gene. | ||||||
Cholecalciferol | 67-97-0 | sc-205630 sc-205630A sc-205630B | 1 g 5 g 10 g | $70.00 $160.00 $290.00 | 2 | |
Cholecalciferol may induce ATP1B3 expression through its active metabolite, calcitriol, which can bind to vitamin D response elements in the gene's promoter, triggering an increase in gene transcription. |